Drugs / IBI345
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05199519 | Dec 2021 → Oct 2022 | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-02-21 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Announces First Patient Dosing of Universal 'Modular' CAR-T Cell product IBI345 innoventbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI345 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05199519 ↗ |
| Modality | Cell therapy | “IBI345 CAR-T cell injection” NCT05199519 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT05199519 ↗ |